SMARTool aims to perform accurate risk stratification of coronary artery disease patients as well as to provide early diagnosis and prediction of disease progression. This is achieved by the acquisition of data from about 263 patients including computed tomography angiographic images, clinical, molecular, biohumoral, exposome, inflammatory and omics data. Data are collected in two time points with a followup period of approximately 5 years. In the first step, data mining techniques are implemented for the estimation of risk stratification. In the next step, patients, who are classified as medium to high risk are considered for coronary imaging and computational modelling of blood flow, plaque growth and stenosis severity assessment. Additionally, patients with increased stenosis are selected for stent deployment. All the above modules are integrated in a cloud-based platform for the clinical decision support (CDSS) of patients with coronary artery disease. The work presents preliminary results employing the SMARTool dataset as well as the concept and architecture of the under development platform.

Download full-text PDF

Source
http://dx.doi.org/10.1109/EMBC.2018.8513131DOI Listing

Publication Analysis

Top Keywords

risk stratification
12
coronary artery
12
artery disease
12
clinical decision
8
decision support
8
diagnosis prediction
8
patients
5
support platform
4
risk
4
platform risk
4

Similar Publications

Background: Real-world COVID-19 vaccine effectiveness (VE) studies are investigating exposures of increasing complexity accounting for time since vaccination. These studies require methods that adjust for the confounding that arises when morbidities and demographics are associated with vaccination and the risk of outcome events. Methods based on propensity scores (PS) are well-suited to this when the exposure is dichotomous, but present challenges when the exposure is multinomial.

View Article and Find Full Text PDF

Living-donor kidney transplantation is the preferred treatment for kidney failure. In the United States, rates of living kidney donation have been stagnant, which is partly related to concerns over medical and financial risks. Recent research has better characterized the risks of living kidney donation, although the field is limited by a lack of robust registries.

View Article and Find Full Text PDF

Background: Low post-operative day (POD) 1 Factor V has been retrospectively associated with graft loss after liver transplantation when stratified by a cutoff of 0.36 U/mL. We aimed to validate this prospectively.

View Article and Find Full Text PDF

Background: Esophageal squamous cell carcinoma (ESCC) exhibits a long latency period and has a significant geographical disparity in incidence, which underscores the need for models predicting the long-term absolute risk adaptable to regional disease burden.

Methods: 31,883 participants in a large-scale population-based screening trial (Hua County, China) were enrolled to develop the model. Severe dysplasia and above (SDA) identified at screening or follow-up were defined as the outcome.

View Article and Find Full Text PDF

Can febrile neutropenia re-invent its self?

Curr Opin Oncol

January 2025

Service de Médecine Oncologique, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Bruxelles, Belgique.

Purpose Of Review: Febrile neutropenia as a complication of cytotoxic chemotherapies, remains a major event in the medical journey of hematology and oncology patients. In this review, we are trying to review the new elements and highlights that are shaping febrile neutropenia in nowadays.

Recent Findings: Introduction of risk-stratification, expanded use of granulocyte-colony stimulating factor and oral treatment for selected patients and rapid administration of antibiotics revolutionized the treatment of febrile neutropenia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!